Craniofacial development relies on coordinated tissue interactions that allow for patterning and growth of the face. We know a priori that the Wingless, fibroblast growth factor, Hedgehog and transforming growth factorbeta growth factor signaling pathways are required for the development of the face, but how they contribute to the shape of the face is largely untested. Here, we test how each signaling pathway contributes to the overall morphology of the zebrafish anterior neurocranium. We tested the contribution of each signaling pathway to the development of the ethmoid plate during three distinct time periods: the time of neural crest migration [10 hour post fertilization (hpf)]; once the neural crest is resident in the face (20 hpf); and finally at the time at which the cartilaginous condensations are being initiated (48 hpf). Using geometric morphometric analysis, we conclude that each signaling pathway contributes to the shape, size and morphology of the ethmoid plate in a dose-, and time-dependent fashion.
Introduction
The face develops from reciprocal and iterative interactions between several tissue types, including the overlying ectoderm, the neural crest-derived mesenchyme, mesoderm and underlying endoderm. The growth and development of the face is controlled by several organizer regions, such as the frontonasal ectodermal zone (FEZ; Hu et al. 2003; Hu & Marcucio, 2009 ), nasal pit (Szabo-Rogers et al. 2009 ), maxillomandibular cleft region (Trumpp et al. 1999 ) and pharyngeal endoderm (Piotrowski & Nusslein-Volhard, 2000) . While these regions direct development of a particular region, they do not tell us how each growth factor signaling pathway contributes globally to face morphology. Additionally, it is unknown if small deviations in the level of growth factor signaling (not at a level that will disrupt organizer function) impact the size and shape of the craniofacial complex.
Orofacial clefting (OFC) is the most common craniofacial anomaly, and occurs approximately in 1/700 live births. OFC has a multifactorial etiology that includes genetic, teratogenic and environmental risk factors that contribute to its development. Genome-wide association studies have identified 36 single nucleotide polymorphisms (SNPs) associated with human OFC (reviewed in Dixon et al. 2011) . The majority of OFC-associated SNPs are found in the non-coding region of the genome, and as such do not have a clear functional consequence in the associated genes. This result suggests that we have much to learn about these genomic variants that precipitate the development of OFC.
To start to understand how these non-coding SNPs could contribute to OFCs, we hypothesize that minor changes in growth factor signaling lead to a morphological change and result in a sensitized environment for the development of OFCs. To test the role of growth factor signaling in altering the morphology of the face, we focused on the development of the zebrafish anterior neurocranium. We chose the anterior neurocranium because it forms the roof of the zebrafish mouth and is easily visualized at 5 days post-fertilization (dpf) by alcian-blue staining. Some authors consider it to be the functional equivalent of the secondary palate in humans, and the anterior region to be a model for cell movements during palatogenesis (Dougherty et al. 2013) . Zebrafish larvae are ideally suited for the analysis of global alterations of growth factor signaling because they can be cultured in treated media and have a cartilaginous craniofacial skeleton by 5 dpf.
We chose to test the role of fibroblast growth factor (FGF), Hedgehog (HH), transforming growth factor-beta (TGF-b) and Wingless (Wnt) signaling in the development of the ethmoid plate. We hypothesized that inhibition of the HH pathway would reduce the area of the ethmoid plate similar to the development of holoprosencephaly. We expected that inhibition of the TGF-b pathway would enlarge the ethmoid plate. We expected that inhibition of the FGF signaling pathway will decrease the size of the ethmoid plate, by disrupting the FEZ, while increased Wnt signaling will enlarge the ethmoid plate.
Materials and methods

Embryo culture
Zebrafish were obtained from the University of Pittsburgh's Aquatic Facility and handled according to IACUC-approved protocols. All embryos were raised at 28°C in E3 water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 , 0.33 mM MgSO 4 ). Inhibitor treatments were performed on cohorts of 10 embryos in a single well of a 24-well plate in 2 mL of E3 water. We added the inhibitors to the media beginning at three time points: 10, 20 or 48 h post-fertilization (hpf) and the larvae were cultured in treated-media until they were collected at 5 dpf (Fig. 1A) . The embryos were dechorinated~48 hpf and the media was changed every 2 days. We used three different concentrations (Table 1) of the following compounds: the TGF-bR1 inhibitors (SB431542, ALK5i; Inman et al. 2002; Laping et al. 2002; Ichida et al. 2009 ), FGFR inhibitor (PD173074; Mohammadi et al. 1998), Wnt agonist (BIO; Miejer et al. 2003) and HH inhibitor (cyclopamine; Stemgent; Chen et al. 2002a,b) . All of the compounds were solubilized in dimethyl sulfoxide (DMSO). With each clutch of embryos we performed two control experiments consisting of embryos grown in plain media as well as DMSO-treated media. This ensured that we were able to control for clutch-to-clutch variation.
Skeletal staining
At 5 dpf, larvae were euthanized in tricaine and then fixed in 4% paraformaldehyde overnight at 4°C. Cartilage staining was performed according to the Knight protocol (Westerfield, 1993) with modifications. After fixation, specimens were washed in distilled water and stained in an acidic 0.015% alcian-blue stain overnight. After staining, the embryos were rehydrated and bleached in a solution of potassium hydroxide (KOH) and hydrogen peroxide (H 2 O 2 ), until we could see the cartilage staining. The remaining background tissues were removed with a borax and trypsin wash. For photography, the final clearing was accomplished with a graded series of KOH/glycerol. Larvae were photographed as soon as they equilibriated in glycerol. Images were acquired on a Leica M165FC dissecting scope, with a DFC450 camera.
Ethmoid plate area analysis
From the images of the ethmoid plate that we captured, we traced the outline of the ethmoid plate, and used ImageJ to calculate its area. We excluded specimens from this analysis that developed only a single rod of cartilage, or a discontinuous ethmoid plate. We compared the area of the ethmoid plates with a treatment using independent measures ANOVA (analysis of variance) with Tukey's HSD post hoc testing using SPSS version 21.
Geometric morphometric analysis of anterior neurocranium
In order to measure and compare anterior neurocranium shape via geometric morphometrics, three landmarks (three circles, Fig. 1C ) and 20 equidistant semi-landmarks (dashed line, Fig. 1C ) were digitized from the 2D images in tpsDig2 (Rohlf, 2005) . Geometric morphometrics provide a way to combine traditional multivariate statistics of shape variation with meaningful visualizations (Bookstein, 1997). Semi-landmarks were included because there were not enough landmarks that could be defined in all dimensions to capture the outline of the shape of the ethmoid plate. However, the equidistant semi-landmarks cannot be considered truly homologous, even though the outlines are homologous, and therefore need to be 'slid' to create a geometric homology between each corresponding point using a method first developed by Bookstein (1997) . There are two different algorithms available to determine the sliding, either minimizing bending energy or the Procrustes distance. The difference between these two were detailed in Perez et al. (2006) . In the present study, semi-landmark homology was established by sliding to minimize Procrustes distance with tpsRelw (Rohlf, 2010) . After the sliding, the semi-landmarks were treated the same way as the traditional landmarks for subsequent geometric morphometric analyses.
All 23 landmarks were then subjected to a Procrustes superimposition, which transforms, rotates and scales the landmark configurations so they are aligned within a common coordinate system (Rohlf, 1993) . The resulting Procrustes coordinates retain the shape information for analysis. The differences in mean shape between the groups were determined via a non-parametric permutation test of Procrustes distance (5000 permutations). Principal components analysis (PCA) was applied to the Procrustes coordinates in order to identify any aspects of shape variation associated with group differences in treatment. All graphs and other statistical output were generated with MORPHOJ version 1.06a (Klingenberg, 2011) .
Results
In this study, we analyzed the effect of the HH, TGF-b, Wnt and FGF signaling pathways during critical periods of ethmoid plate development. We started the treatments at 10, 20 and 48 hpf, and maintained the larvae in treated water until 5 dpf. With these three starting points we targeted the migration, patterning and differentiation stages of the neural crest cells with treatments beginning at 10, 20 and 48 hpf, respectively (Fig. 1A) . We analyzed the area and gross morphology of the alcian-blue-stained ethmoid plate at 5 dpf followed by PCA to describe how the size and shape changed in response to small molecule treatment.
Gross morphological changes resulting from growth factor inhibition
We concentrated our analysis on the morphology of the cartilaginous endplate of the ethmoid plate (Fig. 1B) . We scored whether the individuals developed defects in the cartilaginous plate and its anterior border, as well as the morphology of the trabeculae and polar cartilages. A few morphological changes occurred frequently, including a discontinuous endplate and defects in the anterior border of the ethmoid plate. We scored a discontinuous endplate when no cartilage develops between the distal ends of the two trabeculae suggesting a problem in midline patterning. Defects in the anterior edge suggest defects in cell migration and merging and a cleft-lip phenotype (Dougherty et al. 2013 ).
Inhibition of TGF-bR1 signaling results in ectopic cartilage in the ethmoid plate ALK5 (transforming growth factor beta receptor 1) controls proliferation and differentiation of craniofacial mesenchyme. ALK5 is required for secondary palatogenesis in the mouse (Dudas et al. 2006) . We used two TGFb-R1 antagonists, the specific inhibitor, ALK5i (Ichida et al. 2009) , and the pan-TGFb-R1 antagonist: SB431542 (Inman et al. 2002; Laping et al. 2002) . We found similar morphological variation with both inhibitors (Table 1) ; however, we performed our analyses with ALK5i because it produced more consistent results at lower effective concentrations.
The lowest concentration of ALK5i resulted in no morphological effects (Table 1) . At 1 lM and 5 lM, more than half of the larvae exhibited craniofacial anomalies. The most striking effect of ALK5i is the growth of ectopic cartilage between the polar cartilages (arrow, Fig. 1F,G) . The ectopic cartilage ranged from an ectopic ball of cartilage to a bridge between the paired polar cartilages. In moderately affected individuals, the ethmoid plate is smaller and its distal border is wavy rather than straight. In the severely affected individuals, a single rod of cartilage develops in the midline.
Inhibition of GSK-3 results in a discontinuous ethmoid plate GSK-3 is a promiscuous kinase that functions in multiple signaling pathways, including the Wnt, HH and NFAT/calcineurin pathways; however, GSK-3 function is most well known for its role in the b-catenin destruction complex (Doble & Woodgett, 2003) . GSK-3 is a required anteriorizing factor in Xenopus, and is required for palatogenesis and skull development in the mouse (Liu et al. 2007; SzaboRogers et al. 2016 ). BIO (6-bromoindirubin 3 0 oxime) binds to the ATP binding pocket of both GSK-3a and GSK-3b, and prevents its activity (Meijer et al. 2003) . GSK-3 inhibition resulted in significant dose-dependent morphological defects. At the lowest concentration of BIO treatment (0.1 lM), the ethmoid plate developed normally when treatment was initiated at either 10 or 20 hpf. When treatment started at 10 hpf with 1 lM or 5 lM BIO, the majority of the larvae developed discontinuous ethmoid plates and a smaller anterior neurocranium (arrow, Fig. 1I , J). BIO treatment initiated at 20 hpf resulted in reduced survival of the larvae, and the few that survived (n = 5/5, Table 1 ) did not develop trabeculae or polar cartilages, and had a residual nubbin of cartilage for the ethmoid plate. We found that 5 lM BIO treatment starting at 20 and 48 hpf resulted in larval death within 48 h of treatment.
Loss of HH signaling results in a discontinuous ethmoid plate Hedgehog signaling is required for patterning the midline of the brain and face (Chiang et al. 1996) , as well as for driving outgrowth of the upper face (Hu et al. 2003; Hu & Marcucio, 2009 ). HH signaling is initiated by an extracellular ligand, binding to the Patched receptor and relieving repression on the Smoothened receptor, thus activating an intracellular signaling cascade. The level of HH signaling ultimately results from the relative abundance of three Gli transcription factors that can function as either activators or repressors of HH-responsive transcription (Varjosalo & Taipale, 2008) . Cyclopamine binds to and prevents the activation of the smoothened receptor (Chen et al. 2002a,b) .
When cyclopamine treatment was initiated at both 10 and 20 hpf and continued until 5 dpf, we observed a smaller and discontinuous ethmoid plate (Fig. 1L,M) . These findings are similar to those of Wada et al. (2005) , and milder than Eberhart et al. (2006) . The trabeculae responded differently to cyclopamine treatment, with treatment starting at 10 hpf, the trabeculae were narrowed in the mediolateral axis, while with treatment starting at 20 hpf, expanded the mediolateral axis of the trabeculae. In our experiments, the embryos were most sensitive to HH inhibition starting at 20 hpf, but loss of HH signaling at all time points tested resulted in a dysmorphic ethmoid plate.
Inhibition of FGF signaling results in no morphological change in the ethmoid plate We inhibited FGF signaling with PD173074 inhibitor. PD173074 competes with ATP to bind to the active site of the FGF receptors (Mohammadi et al. 1998) . Only very mild changes in < 20% of the embryos were observed in PD173074 treatment (Table 1 ; Fig. 1O -Q) in any time or dose category. Thus, treatment with PD173074 at these concentrations did not affect the gross morphology of the ethmoid plate in a time-dependent manner. Growth factor signaling controls the size and shape of the ethmoid plate
Loss of growth factor signaling results in smaller ethmoid plates
We traced the outline of the cartilaginous endplate of the ethmoid plate, and calculated its area using ImageJ. When we started treatment at 10 hpf, the mid and high doses of ALK5i, BIO, cyclopamine and PD173074 reduced the area of the endplate ( Fig. 2A ; P < 0.05). Similar results were found with treatment starting at 20 hpf, the low dose of the compounds did not change the area of the ethmoid plate, while the higher doses reduced the area of the endplate ( Fig. 2B ; P < 0.05). When treatment was initiated at 48 hpf, we found that ALK5i and PD173074 had no effect on ethmoid plate area even though we used the same concentrations that reduced ethmoid plate area with treatments starting at 10 and 20 hpf. BIO or cyclopamine treatment at 48 hpf until 5 dpf resulted in a statistically significant reduction in the area of the ethmoid plate ( Fig. 2C ; P < 0.05). These data show that the effective dose of each compound varies significantly during ethmoid plate morphogenesis. Extending these results suggests that the activity level (amplitude) of each signaling pathway varies significantly over time. Therefore, the susceptibility of the larvae depends on both the amplitude and timing of growth factor signaling.
Inhibition of growth factor signaling results in pathwayspecific shape changes From our gross anatomical analysis, we found that inhibitor treatment altered the morphology of the endplate of the ethmoid plate. This allowed us to ask if there were differences between the shape changes induced by each compound. We digitized the ethmoid plates from each treatment using 20 semi-landmarks (Fig. 1C , dashed line) and three landmarks (Fig. 1C, black circles) . We found no differences between the DMSO-treated samples and the control media-treated samples. In comparing any treatment with control, we found the largest difference between Alk5i, BIO and DMSO control in embryos treated from 10 or 20 hpf; while cyclopamine treatment starting at 48 hpf results in the largest Procrustes distances. Consistently, all treatments with PD were the most different from BIO treatment at any stage of treatment (Table 3) . We found that the Procrustes distance permutation test of mean shape difference between groups was significant in each of the mid or high concentration treatments following any treatment at any timepoint (Table 3) . Each inhibitor produced a unique shape change of the endplate (Fig. 3) . We focused our analysis on the mid and high dose-treated larvae, a PCA revealed that the majority of shape changes were accounted for by PC1 and PC2 (10 hpf -71.244%; 20 hpf -78.824%; 48 hpf -78.197%; Fig. 3) . We compared the size and shape changes between the inhibitors at each treatment stage, and found that each signaling pathway alters the size and shape of the ethmoid plate in a unique way.
Small molecule treatment starting at 10 hpf until 5 dpf (Fig. 3A) resulted in all of the treatment groups separating from the control along PC1. The BIO-treated ethmoid plate shape grouped the furthest into the negative PC1 space, which shows a broader and smaller endplate. Alk5i-and cyclopamine-treated specimens trended towards opposite poles of the PC2 axis, with ALK5i on the positive end and cyclopamine on the negative end. These ethmoid plate shapes are differentiated by modulating the location of the proximal border of the ethmoid plate and the trabeculae, as well as the lateral borders of the posterior end of the ethmoid plate. Treatment from 10 hpf to 5 dpf with PD173074 resulted in ethmoid plate morphology that occupied the neutral space along both PCs and shows a relatively tight grouping compared with the other treatment groups.
Similar patterns emerged with treatment at 20 hpf to 5 dpf; all of the compounds differed from the control group along PC1 (Fig. 3B) . We found that treatment with BIO, ALK5i and cyclopamine starting at 20 hpf made the ethmoid plate end plate broader and shorter. ALK5i and cyclopamine contributed to the variation in shape captured along PC2. ALK5i resulted in a longer proximal distal axis of the endplate, while treatment with cyclopamine shortened it. When we initiated treatment at 48 hpf, the effects of the treatments were much less distinct along both PC1 and PC2 (Fig. 3C) . We found that treatment with PD173074 produced a shape opposite to that of the other treatments groups; it trended toward positive PC1 space, while the others trended towards the negative end. The shape associated with the positive space of PC1 is smaller mediolaterally, while ALK5i, cyclopamine and BIO resulted in an expanded mediolateral axis. In the PC2 space, the proximal-distal endplate was smaller in the BIO-treated samples, and enlarged in the ALK5i-and cyclopamine-treated samples. These latter two groups exhibited significant overlap.
In conclusion, treatment with BIO and ALK5i enlarged the area of ethmoid plate endplate, while treatment with cyclopamine and ALK5i modulate the proximal-distal growth of the endplate. The PCA analysis shows that at earlier timepoints the size and shape of mediolateral and proximal-distal axis of the endplate of the ethmoid plate can be changed in a compound-specific way. As development proceeds, the ability to modulate both axes of variation diminishes, and we find with treatment beginning at 48 hpf that the majority of growth factor signaling is concentrated in growth of the mediolateral axis of the ethmoid plate.
Discussion
We observed subtle morphological variation in the ethmoid plate, suggesting that mild alterations in growth factor signaling amplitude result in craniofacial anomalies, and may drive individual variation and susceptibility to teratogenic events. Our study confirms that there is a sensitive period for ethmoid plate morphogenesis and, depending upon the stage and concentration of growth factor signaling, a stereotypical morphological change will result.
In our analysis, we found that growth factor signaling affected the size and shape of the ethmoid plate most with treatment initiated at 10 and 20 hpf. We observed that ALK5i treatment resulted in the induction of novel cartilages between the polar cartilages with treatment starting at 10 and 20 hpf, and the polar cartilages lost the ability to respond to this signal by 48 hpf. This suggests that TGF-b receptor signaling in the stomodeal ectoderm may direct the chondrogenic cascade in the mesenchyme contributing to the polar cartilages. Treatment with cyclopamine, or ALK5i or PD173074, resulted in defects in the border of the endplate of the ethmoid plate. The border was wavy in contrast to the straight border in the DMSO control or the BIOtreated fish. These morphology differences likely reflect changes in the FEZ, and perhaps the development of an OFC phenotype (Hu et al. 2003; Dougherty et al. 2013) .
The trabeculae form the cranial base of the zebrafish. We know a priori that HH signaling in the stomodeal ectoderm for the condensation and patterning of the trabeculae (Wada et al. 2005; Eberhart et al. 2006 ). We did not observe loss of the trabeculae in our treatments, but we did observe discontinuous endplates. The data support a new hypothesis that there could also be a role for TGF-bR1 and WNT signaling in the Pitx1 territory for setting up the shape and size of the trabeculae. Fig. 2 Small molecule treatment decreased the area of the ethmoid endplate in a stage-and dose-dependent manner. We traced the alcian-blue-stained endplate and calculated its area using ImageJ. Depending upon the stage that treatment was initiated at, we observed Alk5i (red), BIO (green), cyclopamine (purple) and PD173074 (yellow) treatment decreased the area of the alcian-blue-stained ethmoid endplate. All of the larvae were treated from either 10, 20 or 48 hpf until 5 dpf at collection. (A) Treatment initiated at 10 hpf with the middle and high dose of all inhibitors (Alk5i, BIO, cyclopamine and PD173074) reduced the area of the ethmoid endplate. (B) Treatment started at 20 hpf reduced the cartilaginous endplate with the highest doses of BIO-, ALK5i-and PD173074-treated larvae, while the cyclopamine treatment had no effect. (C) Treatment initiated at 48 hpf reduced the ethmoid plate endplate area of the BIO-and cyclopamine-treated larvae, but had no affect on the ALK5i-or PD173074-treated larvae. *P < 0.05 compared with control. The errors bars represent standard deviation.
In the treatments with cyclopamine and BIO, we often observed discontinuous endplates. These discontinuities did not stain with alcian blue, suggesting that there are no mature chondrocytes between the trabeculae and represent a dysmorphic cranial base. We hypothesize that these discontinuities formed through two possibilities: loss of inductive signals for their development or the lack of migration of chondrocytes from the midline of the ethmoid plate. We favor the first explanation because the discontinuous ethmoid plate develops from treatment beginning at both 10 or 20 hpf, which correlates when signaling from the stomodeal ectoderm is required for neural crest condensation and induction of the ethmoid plate (Wada et al. 2005; Eberhart et al. 2006) . This leads to the hypothesis that the presumptive pituitary gland is required for cranial base development. In several mouse models that are defective in HH signaling, they also develop fenestrated cranial base cartilages as well as cleft palate (Treier et al. 1998 (Treier et al. , 2001 Khonsari et al. 2013) .
Geometric morphometric analysis is a useful tool for analyzing the effects of treatments on facial development. In this study, we were able to quantify changes that ultimately arose from early treatments with inhibitors. This suggests that to fully understand how growth factor signaling contributes to the development of OFCs, we need to incorporate geometric morphometrics into our analyses of animal models.
Intriguingly, the Procrustes analyses show that each growth factor pathway does change the shape of the ethmoid plate, and show that the shape changes in the PCA are overwhelmed by the changes brought about by BIO and ALK5i. This overwhelming contribution from ALK5i and Statistically significant results (P < 0.05) are shaded gray; exact P-values are presented in Table S1 . ALK5i, ALK5 inhibitor; Cyclo, cyclopamine; DMSO, dimethyl sulfoxide; dpf, days post-fertilization; hpf, hours post-fertilization; PD, PD173074.
BIO is surprising, and could suggest that these inhibitors are more soluble or more bioactive in the zebrafish system. However, we favor the idea that TGF-bR1 and Wnt signaling are leaders of hierarchical signaling that contribute to the shape and form of the trabeculae. The Procrustes analysis also shows dose timing has an effect on the size and shape of the ethmoid plate. The application of inhibitors from 10 hpf to 5 dpf results in the most dramatic shape changes, suggesting that major growth and shape organizers have been affected. Treatment from either 20 hpf or 48 hpf to 5 dpf the growth factor signaling is required for modulating the size and shape of the ethmoid plate, rather than patterning the whole organ. By using the same concentration of small molecule at several different stages, we gaged how the embryo can modulate and respond to altered growth factor signaling. Whether the reduced responses resulted from the ability of the larvae to modulate the response to the pathways by increasing the expression of an agonist is unknown.
We also observed some morphing of shapes, but no large-scale change in the resulting morphology. Loss of HH or TGF-bR1 signaling, and gain of Wnt signaling, results in the same morphological variation -the discontinuous ethmoid plate as well as a reduction in the area of cartilage in the endplate. We also found that the size and shape changes due to treatment with cyclopamine and BIO were not significantly different from each other at 20 and 48 hpf. We hypothesize that these inhibitors function on proteins that converge on the same transcription factors that ultimately result in the ethmoid plate defects. Further work is needed to understand how these morphological and molecular changes that result from small modulations in growth factor signaling contribute to altered face shape, thus creating a sensitized environment that leads to OFC.
Concluding remarks
Based on these analyses, we conclude that HH, Wnt, TGF-b and FGF signaling pathway contribute to the development of mediolateral and proximal-distal axis of the face, and small perturbations of growth factor signaling can alter the shape of the developing face. Further, we were able to generate phenotypic variation easily by changing global growth factor signaling. These studies will be helpful in modeling human phenotypic variation. From this work, we further hypothesize that the SNPs associated with human OFCs may alter growth factor signaling, which in turn predisposes embryos to the development of OFCs. Fig. 3 Stage-and dose-dependent changes to ethmoid plate morphology revealed by geometric morphometric analysis. The first column contains the principal component analysis (PCA) plots, while the second column contains the wire frame representations of the ethmoid plates. The ethmoid plates were digitized after cartilage staining at 5 dpf. The wire frame representations only include the digitized regions of the trabeculae and ethmoid plates illustrated in Fig 1C. The bar connecting the trabeculae represents the location of the distalmost landmark and represents the proximal extent of the ethmoid endplate, while the two dots represent the landmarks that mark the location of the notochord, and the outline is made up of 20 semilandmarks (Fig 1C) . Treatment was initiated at 10 hpf, 20 hpf and 48 hpf, and continued until 5 dpf with ALK5i (red), BIO (green), cyclopamine (purple) and PD173074 (yellow). The treatment with small molecules changed the morphology of the ethmoid plates by affecting the location of the proximal border of the ethmoid plate, as well as the width and length of the cartilage endplate in a stage-specific manner. (A) Treatment initiated at 10 hpf showed separation between BIO treatment and the control and PD173074 treatment in the PC1 axis, while Alk5i and cyclopamine treatment separated along the PC2 axis. (B) Treatment started at 20 hpf separates the ALK5i, BIO and cyclopamine treatments along the PC2 axis, while the PD173074 and mid-dose ALK5i treatments result in ethmoid plates that are morphologically similar to the control samples. Alk5i, cyclopamine and BIO separate on the PC1 axis. (C) Treatment beginning at 48 hpf results in the separating out of the PD173074 into the positive PC1 space, while cyclopamine, BIO and ALK5i remain in the negative PC1 axis.
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